Respiratory Syncytial Virus (RSV) Infection – A Patient‑Friendly Guide
Overview
Respiratory syncytial virus (RSV) is a common viral pathogen that infects the upper and lower respiratory tracts. While most healthy children and adults recover with mild, cold‑like symptoms, RSV is the leading cause of bronchiolitis and pneumonia in infants and a serious illness for older adults and people with weakened immune systems.[1][2]
Who it affects:
- Infants < 1 year old – especially those born prematurely or with congenital heart or lung disease.
- Children 1–5 years – typically experience mild illness, but can develop bronchiolitis.
- Adults over 65 years – risk of severe lower‑respiratory infection comparable to influenza.
- Immunocompromised individuals of any age – higher risk of prolonged infection and complications.
Prevalence: RSV circulates worldwide in seasonal epidemics, usually in fall, winter, and early spring in temperate climates. In the United States, the Centers for Disease Control and Prevention (CDC) estimates ≈57,000 hospitalizations and 120–150 deaths annually among children < 5 years old, and > 10,000 hospitalizations among adults ≥ 65 years.[3]
Symptoms
Symptoms vary with age and severity. Below is a comprehensive list, grouped by system.
Upper‑respiratory symptoms (common in all ages)
- Runny or stuffy nose – often the first sign.
- Sore throat – may feel scratchy.
- Sneezing – particularly in infants and young children.
- Cough – starts dry, can become productive.
- Low‑grade fever – 37.5‑38.5 °C (99.5‑101.5 °F); fever may be absent in older adults.
Lower‑respiratory symptoms (more common in infants, older adults, and high‑risk groups)
- Rapid or shallow breathing (tachypnea) – > 60 breaths/min in infants; > 30 breaths/min in adults.
- Wheezing or whistling sounds – indicates airway narrowing.
- Chest retractions – skin pulling in between ribs or under the breastbone.
- Difficulty feeding or poor appetite – especially in babies due to increased work of breathing.
- Fatigue and irritability – common in infants.
- Blue tint to lips or fingertips (cyanosis) – sign of low oxygen.
Systemic signs (may suggest severe disease)
- Dehydration (dry mouth, no tears, decreased urine output).
- Altered mental status (lethargy, confusion) – especially in older adults.
- High fever > 39 °C (102.2 °F) – less common but warrants evaluation.
Causes and Risk Factors
What causes RSV?
RSV is an RNA virus in the Paramyxoviridae family. It spreads through:
- Respiratory droplets when an infected person coughs or sneezes.
- Direct contact – kissing, sharing utensils, or touching contaminated surfaces then touching the face.
- Fomites – the virus can survive on hard surfaces for up to 6 hours.
The incubation period is typically 4–6 days, and individuals can remain contagious for 3–8 days. Infants and immunocompromised patients may shed the virus for several weeks.[4]
Key risk factors for severe RSV infection
- Prematurity (< 37 weeks gestation) or birth weight < 2,500 g.
- Chronic lung disease of prematurity (bronchopulmonary dysplasia).
- Congenital heart disease, especially cyanotic lesions.
- Neuromuscular disorders that impair cough or airway clearance.
- Immunodeficiency (e.g., chemotherapy, transplant, HIV).
- Adults ≥ 65 years, particularly with COPD, asthma, or heart failure.
- Living in crowded settings (daycares, nursing homes) or exposure to tobacco smoke.
Diagnosis
Diagnosis combines clinical suspicion with laboratory testing.
Clinical assessment
- History of seasonal cough/fever and exposure to other sick individuals.
- Physical exam: nasal congestion, wheezing, crackles, and signs of respiratory distress.
Laboratory tests
- Rapid antigen detection test (RADT) – results in 15–30 minutes; sensitivity 70‑90 % in children, lower in adults.
- Reverse‑transcriptase polymerase chain reaction (RT‑PCR) – gold standard; > 95 % sensitivity, can identify RSV‑A vs. RSV‑B.
- Viral culture – rarely used now due to longer turnaround.
- Complete blood count (CBC) – may show lymphocytosis; not diagnostic.
- Chest radiograph – indicated if pneumonia is suspected; may show hyperinflation or focal infiltrates.
Testing is especially recommended for infants < 3 months, high‑risk adults, or patients with worsening respiratory status.
Treatment Options
There is no cure for RSV; treatment focuses on supportive care and, in selected patients, targeted antivirals.
Supportive care (mainstay for most patients)
- Oxygen therapy – nasal cannula or high‑flow nasal cannula (HFNC) to maintain SpO₂ ≥ 92 %.
- Hydration – oral fluids for mild disease; intravenous fluids for infants who cannot feed.
- Nebulized bronchodilators – trial of albuterol may improve wheeze; evidence mixed.
- Suctioning of nasal secretions – especially in infants, using saline drops and a bulb syringe.
- Fever control – acetaminophen or ibuprofen as appropriate.
Antiviral therapy
- Ribavirin (aerosolized) – FDA‑approved for severe RSV in high‑risk infants; limited availability and modest benefit.[5]
- Palivizumab (monoclonal antibody) – prophylactic (not treatment) monthly injection during RSV season for high‑risk infants; reduces hospitalization by ~55 %.[6]
Advanced respiratory support (for severe cases)
- Continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP).
- Mechanical ventilation – intubation in ICU for respiratory failure.
- Extracorporeal membrane oxygenation (ECMO) – rarely, in refractory hypoxemia.
Lifestyle and home‑care measures
- Elevate the head of the infant’s crib or use a humidifier to ease breathing.
- Encourage frequent small feeds rather than large meals.
- Maintain a smoke‑free environment.
Living with Respiratory Syncytial Virus (RSV) Infection
Even after the acute phase, some patients experience lingering respiratory issues. Below are practical tips for day‑to‑day management.
For Parents of Infants & Young Children
- Monitor breathing rate and look for retractions or worsening wheeze at least every 4 hours.
- Keep a log of temperature, feed volumes, and urine output (wet diapers ≥ 6 / day is reassuring).
- Use saline nasal drops and a bulb syringe before feeds to clear secretions.
- Ensure the child stays hydrated – breast milk or formula is best; offer small, frequent feeds.
- Avoid crowds and limit visitors while the baby is symptomatic.
For Older Adults & High‑Risk Adults
- Use a pulse oximeter at home; seek care if SpO₂ falls < 92 %.
- Stay up‑to‑date on vaccinations (influenza, COVID‑19, pneumococcal) to reduce co‑infection risk.
- Continue inhaled bronchodilators or steroids as prescribed for COPD/asthma.
- Maintain good hand hygiene and avoid close contact with sick individuals.
General Well‑Being
- Rest – sleep supports immune function.
- Nutrition – balanced diet rich in fruits, vegetables, and protein.
- Hydration – aim for ≥ 1 L of fluid per day for adults; more if fever is present.
- Follow‑up – schedule a pediatric or primary‑care visit 1–2 weeks after discharge to ensure recovery.
Prevention
Because RSV spreads easily, prevention relies on both community‑level strategies and individual habits.
- Hand hygiene – wash hands with soap for at least 20 seconds; use alcohol‑based sanitizer if soap unavailable.
- Limit exposure – keep infants < 6 months away from crowded places during peak season.
- Respiratory etiquette – cover coughs/sneezes with a tissue or elbow.
- Environmental cleaning – disinfect toys, countertops, and shared items daily.
- Smoking cessation – eliminate tobacco smoke indoors; second‑hand smoke increases RSV severity.
- Prophylactic Palivizumab – recommended for:
- Premature infants (< 29 weeks gestation) up to 12 months of age.
- Infants with chronic lung disease or congenital heart disease.
- Children with severe immunodeficiency.
- Vaccines in development – several maternal and pediatric RSV vaccines are in phase 3 trials and may become available within the next few years (as of 2024). Keep informed through your health‑care provider.
Complications
If RSV is not adequately managed, it can lead to serious health problems.
- Bronchiolitis – inflammation of small airways; most common cause of hospitalization in infants.
- Pneumonia – bacterial superinfection may occur, especially in the elderly.
- Apnea – especially in preterm infants; pauses in breathing that require monitoring.
- Chronic lung disease – recurrent wheeze or asthma‑like symptoms after severe RSV infection.
- Heart failure exacerbation – in patients with congenital heart disease.
- Secondary bacterial infections – such as otitis media or sinusitis.
- Long‑term neurodevelopmental impact – some studies link severe early RSV infection with later wheezing disorders and reduced lung function.[7]
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if your child or you experience any of the following:
- Breathing rate that is unusually fast or labored (infants: > 60 breaths/min; toddlers: > 40; adults: > 30) or visible chest retractions.
- Persistent high fever > 39 °C (102 °F) that does not improve with medication.
- Blue or gray color around lips, fingertips, or nail beds (cyanosis).
- Severe difficulty feeding or drinking, leading to possible dehydration.
- Sudden change in mental status – confusion, lethargy, or inability to wake.
- Repeated vomiting that prevents keeping fluids down.
- Worsening wheezing or a cough that no longer improves with prescribed inhalers.
- Any sign of seizure activity.
Prompt medical attention can prevent respiratory failure and reduce the risk of long‑term complications.
References
- Mayo Clinic. “Respiratory syncytial virus (RSV) infection” 2023. Link
- CDC. “RSV Surveillance Overview” 2024. Link
- Centers for Disease Control and Prevention. “RSV Hospitalizations and Deaths” 2024. Link
- World Health Organization. “Respiratory syncytial virus: Global epidemiology and burden” 2023. Link
- American Academy of Pediatrics. “Use of Aerosolized Ribavirin for RSV” 2022. Pediatrics. 149(2):e2021050045.
- Palivizumab (Synagis) prescribing information. FDA, 2023. Link
- Hall CB, et al. “Long-term pulmonary outcomes after severe RSV infection in infancy” 2021. J Pediatr. 232:123‑130.e3.